Global Scans · IPSOS · Weekly Summary

• [New] A recent Reuters/Ipsos poll indicated that half of Americans fear that the spread of AI could lead to job losses for themselves or family members. / USA Aju Press
• Americans do not think the short-term pain will be particularly short-lived, either; a Reuters-Ipsos poll this week showed 67% of Americans said they expected gas prices to get worse over 2027. CNN
• 71% of respondents to an August Reuters/Ipsos poll said they are worried that artificial intelligence will put too many people out of work permanently. The Atlantic
• According to another Ipsos/Axios poll, concern about the health risks of traveling on an airplane and returning to a normal, pre-COVID - 19 life had been on a steady decline for a few months, but they spiked back up in December, to 68% and 52%, respectively. / USA FiveThirtyEight
• Despite economic uncertainty, nearly half of Canadians are confident they will take a winter vacation in 2025, up 11 points from last winter, according to an Allianz Global Assistance Canada (Allianz) survey conducted by Ipsos. Ipsos
• A 2025 global survey across 30 countries by IPSOS shows widespread anxiety about international security, with disinformation and hacking ranked as the world's most urgent threats. EU DisinfoLab
• In an Ipsos online poll of 1,117 U.S. adults released this week, only 16% said they are very comfortable about the use of AI for assessing cybersecurity threats. Tenable
• The American Communities Project-Ipsos survey finds pessimism across every community type, with majorities expecting AI to harm daily life, children, and job security. American Enterprise Institute - AEI
• Artificial intelligence could displace 92 million jobs by 2030 while creating 170 million new positions, though a Reuters and Ipsos survey revealed that 71% of Americans fear AI will cause permanent job loss, reflecting public uncertainty about workforce transitions. Insurance Business
• Ipsos comment: With potential CAR-T efficacy and a durable response, glofitamab will provide a readily available choice for CAR-T failures or non-candidates. MM+M - Medical Marketing and Media

Last updated: 21 June 2026